CVS250502C74000
- 0.01
- -0.02-66.67%
CVS Health Newsroom
A Glimpse Into The Expert Outlook On CVS Health Through 10 Analysts
Truist Financial Maintains CVS Health(CVS.US) With Buy Rating, Maintains Target Price $82
BofA Securities Maintains CVS Health(CVS.US) With Buy Rating, Raises Target Price to $85
UBS Maintains CVS Health(CVS.US) With Hold Rating, Raises Target Price to $71
Why Is Novo Nordisk Stock Trading Higher On Friday?
Sector Update: Health Care Stocks Higher Friday Afternoon
DOJ Sues Medicare Insurers Over Alleged Kickback Scheme
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why. -- Barrons.com
Cigna to Launch Specialized GLP-1 Pharmacy Next Month
Research Alert: CFRA Keeps Hold Opinion On Shares Of Cvs Health Corporation
Eli Lilly's Zepbound Likely to Continue Uptake Despite CVS Decision, Truist Says
Eli Lilly's 'Untapped Volume' in Obesity Drug Counters CVS Setback, Deutsche Bank Says
CVS Health Having 'Nice' Start to 2025 on 'Strong' Q1 Results, Cash Flow Generation, Truist Says
Express News | CVS Health Corp : BofA Global Research Raises Price Objective to $85 From $80
CVS Health Analyst Ratings
Stronger-Than-Expected April Jobs Growth Lifts US Equity Futures Pre-Bell
UBS Adjusts CVS Health Price Target to $71 From $67, Maintains Neutral Rating
CVS Health Corporation's (NYSE:CVS) Price Is Out Of Tune With Earnings
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), CVS Health (CVS) and Cytokinetics (CYTK)
Eli Lilly Brushes Off CVS Decision to Drop Zepbound Coverage